BOSTON--(BUSINESS WIRE)--A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.
COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.
“About seven percent of adults in Pennsylvania are living with COPD, and Berks County has a higher rate of COPD-related hospitalization than other parts of the state,” said Dr. Alec Platt, the Care Access Research Investigator for this study in Wyomissing. “Having access to this global study here in Wyomissing is an important opportunity for local residents dealing with this condition.”
The research study is now enrolling for current and former smokers who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.
Care Access opened its doors in Wyomissing in collaboration with local community leaders and healthcare providers seeking to make clinical studies more easily accessible to patients. The local setting provides residents of Wyomissing, Reading, and surrounding communities the option to participate in clinical studies close to home.
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
